News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug interactions and pharmacokinetics news

Show

From To
New and experimental hepatitis C treatment
European Medicines Agency informs doctors and patients about drug interaction between Victrelis and ritonavir-boosted HIV protease inhibitors

The European Medicines Agency has recommended updating the prescribing information for Victrelis (boceprevir) with information about drug interactions between this hepatitis C medicine and the ritonavir-boosted HIV protease inhibitors atazanavir, darunavir and lopinavir.

Published
18 February 2012
From
European Medicines Agency
Hepatitis C treatment
Merck Warns of Victrelis and HIV Protease Inhibitor Interactions

The hepatitis C protease inhibitor Victrelis (boceprevir) has some significant drug-drug interactions with common Norvir (ritonavir)-boosted protease inhibitor (PI) combinations, according to preliminary data from a clinical trial and a warning issued to health care providers by Merck on February 6. 

Published
08 February 2012
From
AIDSMeds
Drug interactions and pharmacokinetics
Combining HCV Med Boceprevir with Boosted HIV Protease Inhibitors Can Lower Drug Levels

HIV/HCV coinfected people who take the HCV protease inhibitor boceprevir (Victrelis) for hepatitis C treatment along with a ritonavir-boosted HIV protease inhibitor may experience drug-drug interactions that reduce concentrations of both drugs to ineffective levels, Merck warned this week.

Published
07 February 2012
From
HIVandHepatitis.com
Prevention of mother-to-child transmission
Can speeding up nevirapine clearance reduce the risk of resistance after PMTCT use?

In a bid to reduce the risk of nevirapine resistance after the use of single-dose nevirapine to prevent mother-to-child HIV transmission, several research groups are now experimenting with

Published
20 January 2012
By
Carole Leach-Lemens
Drug interactions and pharmacokinetics
Guidelines published on management of interactions between anti-epileptic and anti-HIV drugs

Doses adjustments are required when certain antiretrovirals and anti-epileptic drugs are taken together, according to guidelines published in Neurology.  The guidelines were developed by a team of

Published
09 January 2012
By
Michael Carter
Drug interactions and pharmacokinetics
Guidelines stress caution when combining anti-epileptic, HIV drugs

New guidelines will help physicians better choose seizure drugs for people on HIV/AIDS medication, avoiding deadly drug interactions and preventing critical anti-HIV drugs from becoming less effective, possibly leading to a more virulent strain of the disease.

Published
04 January 2012
From
Science Daily
Drug interactions and pharmacokinetics
Guidelines stress caution when combining anti-epileptic, HIV drugs

New guidelines from the American Academy of Neurology will help physicians better choose seizure drugs for people on HIV/AIDS medication, avoiding deadly drug interactions and preventing critical anti-HIV drugs from becoming less effective, possibly leading to a more virulent strain of the disease.

Published
04 January 2012
From
Medical Xpress
New and experimental HIV treatments
BMS to develop Reyataz fixed-dose pill with Gilead booster drug

Bristol-Myers Squibb and Gilead Sciences, Inc. today announced a licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing Bristol-Myers Squibb's protease inhibitor Reyataz (atazanavir sulfate) and Gilead's cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain HIV medicines to potentially allow for one pill once daily dosing.

Published
26 October 2011
From
MarketWatch
Pharmaceutical industry
Innovative transdermal patch for delivery of HIV medicine

An innovative delivery method for human immunodeficiency virus medications has been developed through use of a transdermal patch, the first of its kind to treat HIV.

Published
25 October 2011
From
Science Daily
New and experimental hepatitis C treatment
ICAAC: HCV Drug Telaprevir Shows No Problematic Interactions with Raltegravir

The new hepatitis C virus (HCV) protease inhibitor telaprevir (Incivek) does not appear to have clinically relevant drug-drug interactions with the HIV integrase inhibitor raltegravir (Isentress), according to a study presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) last month in Chicago.

Published
06 October 2011
From
HIVandhepatitis.com
← Prev1...23456...14Next →

Filter by country